1. Turner, NC, Ro, J, André, F, et al. Palbociclib in hormone-receptor–positive advanced breast cancer. N Engl J Med. 2015;373:209-219.
Google Scholar | Crossref | Medline | ISI2. Finn, RS, Martin, M, Rugo, HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925-1936.
Google Scholar | Crossref | Medline | ISI3. Goetz, MP, Toi, M, Campone, M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638-3646.
Google Scholar | Crossref | Medline4. Sledge, GW, Toi, M, Neven, P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy – MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116-124.
Google Scholar | Crossref | Medline5. Turner, NC, Liu, Y, Zhu, Z, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2019;37:1169-1178.
Google Scholar | Crossref | Medline6. O’Leary, B, Hrebien, S, Morden, JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018;9:896.
Google Scholar | Crossref | Medline7. Bagegni, N, Thomas, S, Liu, N, et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res. 2017;19:123.
Google Scholar | Crossref | Medline8. Odan, N, Kikawa, Y, Matsumoto, H, et al. Real-world outcomes of treating advanced breast cancer patients with palbociclib: a multicenter retrospective cohort study in Japan-the KBCOG-14 study. Breast Cancer. 2020;14:1-7.
Google Scholar9. Raspé, E, Coulonval, K, Pita, JM, et al. CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Mol Med. 2017;9:1052-1066.
Google Scholar | Crossref | Medline10. Portman, N, Milioli, HH, Alexandrou, S, et al. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Res. 2020;22:87.
Google Scholar | Crossref | Medline11. Formisano, L, Lu, Y, Servetto, A, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10:1373.
Google Scholar | Crossref | Medline12. Robbins, P, Pinder, S, de Klerk, N, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol. 1995;26:873-879.
Google Scholar | Crossref | Medline | ISI13. Allred, DC, Harvey, JM, Berardo, M, Clark, GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
Google Scholar | Medline | ISI14. Ethier, JL, Desautels, D, Templeton, A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19:2.
Google Scholar | Crossref | Medline15. Koh, CH, Bhoo-Pathy, N, Ng, KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113:150-158.
Google Scholar | Crossref | Medline16. De Larco, JE, Wuertz, BR, Furcht, LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res. 2004;10:4895-4900.
Google Scholar | Crossref | Medline17. el-Hag, A, Clark, RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987;139:2406-2413.
Google Scholar | Medline18. Chen, Y, Chen, K, Xiao, X, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer. 2016;16:320.
Google Scholar | Crossref | Medline19. Asano, Y, Kashiwagi, S, Onoda, N, et al. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast cancer. Ann Surg Oncol. 2016;23:1104-1110.
Google Scholar | Crossref | Medline20. Myojin, M, Horimoto, Y, Ito, M, et al. Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer. Breast Cancer. 2020;27:732-738.
Google Scholar | Crossref | Medline21. Cardoso, F, Paluch-Shimon, S, Senkus, E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623-1649.
Google Scholar | Crossref | Medline22. Emens, LA, Molinero, L, Loi, S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the impassion 130 study. J Natl Cancer Inst. 2021;113:1005-1016.
Google Scholar | Crossref | Medline23. Dieci, MV, Barbieri, E, Piacentini, F, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013;24:101-108.
Google Scholar | Crossref | Medline24. Amir, E, Miller, N, Geddie, W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30:587-592.
Google Scholar | Crossref | Medline | ISI25. Thompson, AM, Jordan, LB, Quinlan, P, et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010;12:R92.
Google Scholar | Crossref26. Watanabe, J . Reply to letters to the editor: discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer. Breast Cancer Res Treat. 2020;182:513-514.
Google Scholar | Crossref | Medline27. Horimoto, Y, Tokuda, E, Murakami, F, et al. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study. J Transl Med. 2018;16:287.
Google Scholar | Crossref | Medline28. Rugo, HS, Finn, RS, Diéras, V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719-729.
Google Scholar | Crossref | Medline29. Battisti, NML, Kingston, B, King, J, et al. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience. Breast Cancer Res Treat. 2019;174:731-740.
Google Scholar | Crossref | Medline30. Turner, NC, Finn, RS, Martin, M, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018;29:669-680.
Google Scholar | Crossref | Medline31. Masuda, N, Nishimura, R, Takahashi, M, et al. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: a Japanese phase II study. Cancer Sci. 2018;109:803-813.
Google Scholar | Crossref | Medline